Dattola A, et al. - An inspection was carried out of the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent for the treatment of rheumatoid arthritis and psoriatic arthritis (PsA). The inference drawn was that CZP could be used safely and effectively to treat both the cutaneous and joint components of PsA. In order to validate the yielded results, prospective trials were required.